

Advancing the future of gastrointestinal oncology: a call for collaborative excellence

Jia Wei*

Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China

* Corresponding author, E-mail: jiawei99@nju.edu.cn


Gastrointestinal (GI) tumors are a growing global health concern, with late-stage diagnoses making treatment challenging. Despite advances in molecular biology and new therapies, effective management remains formidable. Genetic predispositions, environmental factors, and unhealthy lifestyles further complicate their prevention. As we deepen our understanding of tumor microenvironments and signaling pathways, the importance of targeted, personalized treatments becomes increasingly evident. Therefore, continued research and advanced clinical practices are essential for improving outcomes in gastrointestinal oncology.

I am Dr. Jia Wei, a medical oncologist and professor at the Comprehensive Cancer Center of Drum Tower Hospital, affiliated to Medical School of Nanjing University (Nanjing, China). It is with great enthusiasm that I assume the role of Editor-in-Chief of the Journal of *GI Tumors*. This journal had a proud history of publishing innovative and impactful research and served as a platform for advancing the understanding, diagnosis, and treatment of gastrointestinal tumors. I am honored to continue this legacy and promise to work closely with our esteemed editorial board, dedicated authors, engaged readers, and the vibrant new publisher, Maximum Academic Press, to further elevate the journal's standing in the scientific community.

The field of GI oncology is evolving rapidly, with breakthroughs in immunotherapy, biomarker development, precision medicine, and advanced imaging techniques. These new developments are revolutionizing how we understand and treat GI tumors. However, significant challenges remain, from tackling hard-to-treat cancers, such as pancreatic adenocarcinoma metastatic gastric cancer relapsed from standard therapy, to addressing the rising incidence of early-onset colorectal cancer. These issues demand collaborative, interdisciplinary efforts and the dissemination of robust, high-quality research that highlights advancements in immunotherapy, targeted therapy, biomarkers, and personalized medicine.

The journal is dedicated to publishing high-quality, innovative research that spans the spectrum from basic science to clinical practice, with the ultimate goal of improving the understanding, diagnosis, treatment, and prevention of GI tumors. We welcome

submissions of various types, including review articles, research articles, case reports, editorials, perspectives, letters, and systematic reviews. All dedicated professionals in the field of GI tumor research are invited to join our editorial board, whose expertise and insight will better serve our authors and readers. We promise to work with authors, reviewers, and the publisher to ensure a rigorous, yet efficient peer-review process, to make publishing faster and more straightforward. As we continue to face complex challenges in GI tumor research, collective efforts are essential to drive global research and discoveries. Together, let us establish this journal as a beacon for groundbreaking discoveries and transformative ideas. For submission guidelines and further information, please visit our website at www.maxapress.com/git. I am excited to embark on this journey with you and look forward to your valuable contributions as we shape the future of research on GI tumors.



Conflict of interest

The author declares that there is no conflict of interest.

Dates

Received 4 December 2024; Revised 4 December 2024; Accepted 4 December 2024; Published online 19 December 2024



Copyright: © 2024 by the author(s). Published by Maximum Academic Press, Fayetteville, GA. This article is an open access article distributed under Creative Commons Attribution License (CC BY 4.0), visit <https://creativecommons.org/licenses/by/4.0/>.